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Parkinson's diseaseThe lysosomal hydrolase glucocerebrosidase (GCase) is encoded for by the GBA gene. Homozygous GBAmuta-
tions cause Gaucher disease (GD), a lysosomal storage disorder. Furthermore, homozygous and heterozygous
GBAmutations are numerically the greatest genetic risk factor for developing Parkinson's disease (PD), the sec-
ond most common neurodegenerative disorder. The loss of GCase activity results in impairment of the autopha-
gy‐lysosome pathway (ALP), which is required for the degradation of macromolecules and damaged organelles.
Aberrant protein handling ofα-synuclein by the ALP occurs in both GD and PD.α-synuclein is the principle com-
ponent of Lewy bodies, a deﬁning hallmark of PD.Mitochondrial dysfunction is also observed in both GD and PD.
In this review we will describe how mitochondria are affected following loss of GCase activity. The pathogenic
mechanisms leading to mitochondria dysfunction will also be discussed, focusing on the likely inhibition of the
degradation of mitochondria by the ALP, also termedmitophagy. Other pathogenic cellular processes associated
with GBAmutations that might contribute, such as the unfolding of GCase in the endoplasmic reticulum, calcium
dysregulation and neuroinﬂammation will also be described. Impairment of the ALP and mitochondria dysfunc-
tion are common pathogenic themes between GD and PD and probably explain why GBAmutations increase the
risk of developing PD that is very similar to sporadic forms of the disease.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Glucocerebrosidase
Glucocerebrosidase (GCase; also known as glucosylceramidase; EC
3.2.1.45) is a lysosomal enzyme involved in sphingolipid metabolism.
GCase catabolises the substrate glucosylceramide (GlcCer) to glucose
and ceramide. Ceramide is the hydrophobic membrane anchor of
all sphingolipids and is recycled to generate new glycosphingolipids
(e.g. gangliosides such as GM1, GM2, sulfatide) and sphingomyelins
(van Echten-Deckert and Herget, 2006).
GCase is encoded by theGBA gene located on chromosome1q21 and
is comprised of 11 exons, encoding for a protein of approximately
62 kDa. Upon translation, GCase is transported to the lysosome by bind-
ing to the transport receptor LIMP-2 in the endoplasmic reticulum
(Reczek et al., 2007).1.1. Gaucher disease
Autosomal recessive GBA mutations (homozygous or compound
heterozygote) cause Gaucher disease (GD), themost common lysosom-
al storage disorder. Over 300 GBA mutations have been identiﬁed toeuroscience, UCL Institute of
on NW3 2PF, UK.
.
ect.com).
. This is an open access article undercause GD (Hruska et al., 2008; Sidransky et al., 2009). Mutations lead
to loss of GCase activity in the lysosome, resulting in the accumulation
of GlcCer (Nilsson and Svennerholm, 1982; Nilsson et al., 1985). Accu-
mulation of substrate in the lysosomes of macrophages is the main
manifestation in visceral organs, leading to hepatosplenomegaly, anae-
mia, thrombocytopenia and bone involvement (Grabowski, 2008).
While the above manifestations are common to all GD patients, GD is
further classiﬁed in to non-neuronopathic (Type 1; OMIM#2308000)
and neuronopathic (types 2 and 3; OMIM#23099 and OMIM 2301000,
respectively). Onset of type 1 occurs in childhood or adulthood. Type 2
is the most severe, with substantial neurodegeneration and a median
age of death at 9 months. Type 3 also has neurodegeneration, with
death in childhood or early adulthood (Grabowski, 2008).
GBAmutations include point mutations, insertions, deletions, frame
shifts, splice-site alterations and recombinant alleles, with patients
showing considerable clinical heterogeneity despite similar genotypes.
However, the mutant N370S allele, even in combination with another
GBA mutant allele is predictive of Type 1 GD (Grabowski, 2008; Sun
et al., 2013). Furthermore the L444P allele is strongly associated with
neuronopathic GD, with a combination of L444P and another complex
allele leading to type 2, and homozygous L444Pmutations resulting in
type 3. The N370S and L444P allele are the most common mutations
associated with GD (Hruska et al., 2008).
Studies have shown that the intrinsic catalytic activity of N370S and
L444P mutant GCase to be reduced by 80–95% compared to wild-typethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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and molecular dynamic studies have suggested that N370S GCase is
less able to associate with the physiological GCase activator saposin C
and anionic phospholipids (Offman et al., 2010; Salvioli et al., 2005).
However, loss of GCase activity is not solely due to impaired catalytic
activity, but also a reduction in GCase protein levels. Many GCasemuta-
tions, including N370S and L444P, unfold in the endoplasmic reticulum
(ER) at neutral pH, whereupon they are extracted by chaperones and
degraded by the proteasome (Mu et al., 2008; Ron and Horowitz,
2005). This process is known as ER-associated degradation (ERAD).
1.2. Parkinson's disease
Parkinson's disease (PD) is the secondmost commonneurodegener-
ative disorder. The loss of dopaminergic neurons in the substantia nigra
results in movement disorders such as resting tremor, bradykinesia, ri-
gidity and postural instability (Schapira and Jenner, 2011). In addition
to neurodegeneration, PD is characterised by the presence of Lewy bod-
ies in surviving neurons, intracellular protein inclusions predominantly
consisting of α-synuclein. Mitochondrial dysfunction is also associated
with PD pathogenesis (reviewed by Schapira and Gegg, 2011).
Decreased activity of complex I of the electron transport chain (ETC)
occurs in the substantia nigra of PD brains (Schapira et al., 1989). Sever-
al genes associated with early-onset autosomal recessive PD such as DJ-
1, parkin and PINK1 have further strengthened the link between
mitochondria and PD (Bonifati et al., 2003; Kitada et al., 1998; Valente
et al., 2004). In particular, PINK1, a mitochondrial serine threonine ki-
nase, and parkin, an E3 ubiquitin ligase, have recently been identiﬁed
as key players in the identiﬁcation and removal of damaged mitochon-
dria by macroautophagy (Matsuda et al., 2010; Narendra et al., 2008;
Vives-Bauza et al., 2010). The role of impaired autophagy in both PD
and GD will be discussed further below.
1.3. GBA mutations and PD
In 1996 it was ﬁrst reported that some type 1 GD patients exhibited
typical Parkinsonism (Neudorfer et al., 1996). Further investigations
then indicated that people with heterozygote GBA mutations were at
greater risk of developing PD. A multicenter meta-analysis containing
over 5000 PD patients reported the odds ratio of a PD patient carrying
a GBA mutation to be 5.4 (Sidransky et al., 2009). Approximately 5–
10% of PD patients carry a GBAmutation, making these mutations the
most numerical genetic risk factor for developing PD. See Table 1 for a
table summarising the main studies linking GBA with PD.
The age of onset of PD in patients with GBA mutations is approxi-
mately 5 years earlier than sporadic PD cases (Neumann et al., 2009;
Sidransky et al., 2009). GBA-associated parkinsonism resembles sporad-
ic PD, with no noticeable changes in Lewy body pathology reportedTable 1
Summary of main studies linking GBA and PD.
Links between mutant GBA and PD References
Subset of GD patients develop
parkinsonism
Bembi et al. (2003), Neudorfer et al.
(1996), Tayebi et al. (2001)
Genetic multi-centre study reporting
statistically signiﬁcant association
between GBAmutations and PD
Sidransky et al. (2009)
Lewy bodies similar in PD brains with
and without GBAmutations
Neumann et al. (2009), Parkkinen
et al. (2011)
Accumulation and impaired turnover of
α-synuclein in animal and cell models
of GCase deﬁciency
Cullen et al. (2011), Fishbein et al.
(2014), Manning-Boğ et al. (2009),
Mazzulli et al. (2011), Osellame et al.
(2013), Sardi et al. (2011), Schöndorf
et al. (2014)
GCase activity decreased in sporadic PD Gegg et al. (2012), Murphy et al. (2014)
α-synuclein affects GCase function Gegg et al. (2012), Mazzulli et al. (2011),
Sardi et al. (2013), Yap et al. (2011)either (Neumann et al., 2009; Parkkinen et al., 2011). However, cogni-
tive impairment is more frequent in PD patients with GBA mutations
(Alcalay et al., 2012; Beavan et al., 2015; Brockmann et al., 2011). It
should be noted that GBA mutations are also signiﬁcantly associated
with developing dementiawith Lewybodies (DLB) and PDwith demen-
tia (odds ratios of 8.3 and 6.5, respectively; Nalls et al., 2013).
The twomost frequentGBAmutations associatedwith PD are N370S
and L444P, accounting for up to 17–31% of all PD patients in the
European Ashkenazi Jewish population, and 3% in non-Ashkenazi popu-
lations (Neumann et al., 2009; Sidransky et al., 2009). Biochemical anal-
ysis of PD brains with GBAmutations indicated a signiﬁcant decrease in
GCase activity, with the greatest deﬁciency (58%decrease in enzyme ac-
tivity) occurring in the substantia nigra (Gegg et al., 2012).Western blot
analysis indicated that this loss of activity was in part due to a decrease
in protein expression. Markers of the unfolded protein response (UPR)
were increased in PD brains with GBA mutations, suggesting that mu-
tant GCase is degraded by ERAD (Gegg et al., 2012).
Notably, GCase activity and protein expressionwas also signiﬁcantly
decreased by 33% in the substantia nigra of sporadic PD brains (Gegg
et al., 2012). Another study indicated that GCase protein expression
was signiﬁcantly decreased in the anterior cingulate cortex of sporadic
PD brains (Murphy et al., 2014). This study also showed that the
decreased GCase protein levels in the brain signiﬁcantly correlated
with increased α-synuclein levels. This supports cell culture studies
that had indicated that increased α-synuclein levels decreased GCase
protein levels by inhibiting the trafﬁcking of GCase to the lysosome
(Gegg et al., 2012; Mazzulli et al., 2011).
1.4. Lysosomal dysfunction in GD and PD
The accumulation of GlcCer in lysosomes of GD patients and thewell
documented lysosomal dysfunction associated with PD (Alvarez-Erviti
et al., 2010; Cuervo et al., 2004; Dehay et al., 2010), has meant that
much of the GCase research in recent years has focused on the autoph-
agy lysosome pathway (ALP). However it is important to note that the
mechanisms leading to GD and GD patients developing PD are unlikely
to be identical to PD patients with heterozygote GBA mutations. The
greatest disparity is likely to be the accumulation of GlcCer and GlcSph
in peripheral organs and brains of type 1, 2 and 3 GD patients (Nilsson
and Svennerholm, 1982; Nilsson et al., 1985; Orvisky et al., 2002).
Mouse models of neuronopathic GD models also have accumulation in
the brain (Enquist et al., 2007; Farfel-Becker et al., 2014; Sun et al.,
2013). However, no accumulation of GlcCer or GlcSph was detected in
PD brains with heterozygote GBA mutations (Gegg et al., 2015), or
mouse models lacking one of the GBA alleles (GBA+/−; Farfel-Becker
et al., 2014; Sardi et al., 2011). Analysis of whole brain homogenates
does not differentiate between neurons, glia and other cell types in
the brain. A very modest accumulation of GlcCer has been reported in
cortical mouse neurons with 50% decreased GCase activity following
knock down (KD) with RNAi (Mazzulli et al., 2011)and in neurons dif-
ferentiated from inducible pluripotent stem cells (iPSC) containing het-
erozygote GBAmutations (Schöndorf et al., 2014).
While it is still unclear exactly how GBA mutations impact on lyso-
somal function, it is evident that loss of GCase activity effects the ALP
in both heterozygote and homozygote GBA models. Two processes of
the ALP are particularly relevant to GCase deﬁciency: chaperone medi-
ated autophagy (CMA) and macroautophagy (Fig. 1). CMA involves
the degradation of soluble proteins containing a KFERQ pentapeptide
motif. Unfolded proteins are delivered to the lysosome via the chaper-
one hsc70, and the proteins are then directly translocated in to the
lysosome for degradation via the integral membrane protein LAMP2A
(reviewed by Mizushima et al., 2008; Parzych and Klionsky, 2014).
Macroautophagy also degrades macromolecules such as protein and
lipids, but also has the capacity to degrade larger structures, such as
aggregated proteins and damaged organelles like mitochondria
(Mizushima et al., 2008; Parzych and Klionsky, 2014). Cargo for
Fig. 1.Macroautophagy and chaperone mediated autophagy pathways. (A) Macromolecules such as protein and lipids (green square), aggregated proteins (red ﬁbrils) or damaged mi-
tochondria (see inset) are recruited to phagophores by binding to LC3-II embedded in the membrane (orange segments). Phagophores mature into double membrane autophagosomes
thus sequestering cargo for degradation. Following fusion with lysosomes to form an autolysosome, macromolecules and organelles are degraded by degradative enzymes from the lyso-
some. Inset: damagedmitochondria havedecreasedΨmcausing accumulation of full length PINK1 on theOMM. This recruits and phosphorylates the E3 ubiquitin ligase parkin (park) and
ubiquitin (ubq; orange star), resulting in ubiquitination of proteins in the OMM (white cross). These proteins can then be bound by p62 (green teardrop) that enables binding to LC3-II on
the phagophore. Other mitophagy receptors (white triangle) that can bind LC3-II such as FUNDC1, BNIP and cardiolipin are also up regulated following mitophagy induction.
(B) Chaperone mediated autophagy degrades proteins with the pentapeptide motif KFREQ (approximately 30% of cellular proteins contain this motif). Unfolded protein is bound by
hsc70, which then directly delivers protein to lysosomes for degradation via the integral protein LAMP2A.
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expands to form a double-membrane cytosolic vesicle, known as an
autophagsosome. The autophagosome then fuses with lysosomes,
resulting in degradation of the inner membrane of the autophagosome
and its sequestered cargo. Degradation of α-synuclein can occur via
both CMA and macroautophagy.
Inhibition of GCase activity with the toxin conduritol β epoxide
(CBE) resulted in the accumulation of α-synuclein in differentiated
SH-SY5Y cells or in the brains of mice, just 48 h after administration
(Manning-Boğ et al., 2009; Cleeter et al., 2013). The accumulation of
α-synuclein has since been reported in primary neurons with GBA KD
(50% loss of activity; Mazzulli et al., 2011), neurons differentiated
from iPSC derived from GD patients and those carrying heterozygous
GBAmutations (Mazzulli et al., 2011; Schöndorf et al., 2014) or in the
brains of GD mouse models (Cullen et al., 2011; Mazzulli et al., 2011;
Sardi et al., 2011; Osellame et al., 2013). The accumulation of α-
synuclein in the brains of the D409V/D409V GDmouse model (e.g. hip-
pocampus, cerebral cortex) were progressive, proteinase K-resistant
and positive for ubiquitin, sharing characteristics with Lewy bodies
found in PD (Sardi et al., 2011). Memory deﬁcits were also associated
with α-synuclein accumulation, and both could be ameliorated by
injection of adeno-associated viral vectors encoding human GCase
(Sardi et al., 2013, 2011). Soluble and insoluble α-synuclein species
have also been reported in another GD mouse model (V394L/V394L
crossed on to the hypomorphic prosaposin mutant mice; Mazzulliet al., 2011). The authors also showed that GlcCer can also stabilise
soluble oligomeric α-synuclein species in vitro (Mazzulli et al., 2011).
Primary neurons with approximately 50% GCase KD exhibited in-
creased LC3-II levels, while GD neurons generated from iPSC had com-
promised proteolysis of long-lived proteins indicating that autophagy
is affected by GCase deﬁciency (Mazzulli et al., 2011). The turnover of
α-synuclein in L444P/wt mice carrying either human wild-type α-
synuclein or human A53T α-synuclein was found to be decreased
(Fishbein et al., 2014). Furthermore, the motor and gastro-intestinal
deﬁcits observed in the A53T mouse model were exacerbated when
crossed with the L444P/wt mice (Fishbein et al., 2014). Inhibition of
macroautophagy ﬂux has been reported in primary neuronal cultures
derived from GBA knock out (KO)mice (Osellame et al., 2013) and
human neurons differentiated from iPSC derived from GD patients and
people with heterozygote GBAmutations (Schöndorf et al., 2014). This
inhibition was coincident withα-synuclein accumulation. The accumu-
lation of α-synuclein in cell culture models over expressing mutant
GCase could also be reversed by treatment with the macroautophagy
activator rapamycin (Cullen et al., 2011). These data all indicate that
the ALP is impaired with either heterozygote or homozygote GBA
mutations.
Recent studies have strongly implicated the cell to cell transmission
of misfolded proteins such as α-synuclein in the onset and progression
of neurodegenerative disorders such as PD (Guo and Lee, 2014; Luk
et al., 2012). Genetic ablation of GBA by zinc ﬁnger technology in SH-
Fig. 2. Putative pathogenic mechanisms for mitochondrial dysfunction following a loss of
GCase activity. Themitochondrial dysfunction (loss ofΨm, ETC inhibition, reactive oxygen
species (ROS)) observed following decreased GCase activity is most likely to be a result of
inhibition of macroautophagy resulting in damaged mitochondria not being degraded by
mitophagy. Inhibition of autophagic pathways also results in accumulation ofα-synuclein,
which can impair mitochondrial function. Dysregulation of calcium is another route by
which mitochondrial function can be compromised. Increased calcium release from the
ER is observed in GBA mutant cells. This in part is likely due to mutant GCase (mut)
unfolding in the ER and activating ER stress. Neuroinﬂammation occurs in GD brains and
mouse models. The production of NO by activated astrocytes and microglia will damage
the mitochondrial ETC.
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2014). Furthermore, when these cells were injected into the hippocam-
pus of a transgenic mouse expressing humanα-synuclein, the accumu-
lation of host α-synuclein in the graft SH-SY5Y cells lacking GBA
expression was greater than normal SH-SY5Y grafts (Bae et al., 2014).
1.5. Mitochondrial dysfunction and GBA
Loss of GCase activity in brain cells also results in loss of mitochon-
drial function. Inhibition of GCase by CBE in SH-SY5Y neuroblastoma
cells resulted in a signiﬁcant decrease in mitochondrial membrane po-
tential (ψm) after 10 days, and decreased progressively up to 30 days
of CBE treatment (Cleeter et al., 2013). Similarly, GCase KD with
shRNA constructs decreased ψm (Cleeter et al., 2013). Generation of
ψm by the mitochondrial ETC is used to drive the phosphorylation of
ADP to form ATP. In CBE-treated cells, the phosphorylation of ADP was
signiﬁcantly inhibited after 20 days when glutamate and malate (com-
plexes I, III, IV) or succinate (complexes II, III, IV) were used as sub-
strates. However, ADP phosphorylation via complex IV only (ascorbate
and TMPD as substrates)was unaffected (Cleeter et al., 2013). This inhi-
bition of the ETCwas coincidentwith an increase in oxidative stress and
fragmentation of mitochondria.
Mitochondrial dysfunction has also been reported to occur in GD
ﬁbroblasts and GD mouse models. Dermal ﬁbroblasts from three GD
patients (L444P/L444P) exhibited impaired oxygen consumption
when substrates for complex I, II, III and II + III of the ETC were used
(de la Mata et al., 2015). Complex IV activity was not investigated.
Notably, the levels of the respiratory chain electron carrier coenzyme
Q10 (CoQ10) were reduced by 24% in these GD ﬁbroblasts. ATP levels
were decreased by 30% in these ﬁbroblasts and there was decreased
MitoTracker Red staining, suggestive of decreased ψm. Increased pro-
duction of the free radical superoxide by mitochondria was also detect-
ed (de la Mata et al., 2015).
Single cell analysis of astrocytes and neurons derived from a type II
GD KO mouse model indicated a loss of ψm (Osellame et al., 2013).
Similar to the CBE model above, the activities of complex I, and II/III,
but not complex IV, were inhibited in these mixed neuron–glia cul-
tures (Osellame et al., 2013). Oxygen consumption (either basal or
uncoupled) was consequently inhibited, and once again, mitochon-
dria were also more fragmented in cells lacking GCase activity
(Osellame et al., 2013).
The morphology of mitochondria in the cortices of a GD mouse
model (D409H/D409H with hypomorphic prosaposin; 12 weeks old)
was also affected as measured by electron microscopy (Xu et al.,
2014).Mitochondria in thesemice appeared to have lost cristae orga-
nisation, and were more rounded and electron dense. Steady-state
ATP levels and basal mitochondria oxygen consumption were both
decreased in the cortices of this mouse model, and four others
(hypomorphic prosaposin, D409H/D409H, V394L/V394L, V394L/
V394L with hypomorphic prosaposin). Inhibition of primary cortical
neurons treated with CBE for 7 days also exhibited decreased oxygen
consumption and lower steady-state ATP levels (Xu et al., 2014).
1.6. Pathogenicmechanisms formitochondrial dysfunction following loss of
GCase activity
The loss of mitochondrial function in GCase deﬁcient cells could be
explained by impairment of the ALP, changes in cellular lipid/sterol
metabolism, neuroinﬂammation, perturbed calcium homeostasis or a
combination of the above (Fig. 2).
Damaged mitochondria are degraded by macroautophagy, and is
also termed mitophagy (Kim et al., 2007; Tolkovsky et al., 2002).
Mitochondria undergo fusion and ﬁssion forming a dynamic network
within the cell. When mitochondria are damaged, they lose ψm,
which results inﬁssion from thenetwork,whereupon they are recruited
to a phagophore membrane for subsequent degradation (Twig et al.,2008; Fig. 1). Damaged mitochondria are selectively recruited to
phagophores because they become decorated with several autophagic
receptors that bind to LC3-II, which is embedded in the phagophore
membrane. The mitochondrial serine/threonine kinase PINK1 and the
E3 ubiquitin ligase parkin are two such proteins that are involved in
identifyingmitochondria that need to be degraded. Autosomal recessive
mutations in the PINK1 and parkin genes are a cause of early-onset
familial PD (Kitada et al., 1998; Valente et al., 2004). Loss of ψm leads
to the accumulation of full length PINK1 on the outer mitochondrial
membrane (OMM), which then recruits parkin (Matsuda et al., 2010;
Narendra et al., 2010; Vives-Bauza et al., 2010). PINK1-mediated phos-
phorylation of both parkin and ubiquitin (Kazlauskaite et al., 2014;
Koyano et al., 2014) results in the ubiquitination of many OMM pro-
teins, including VDAC1, mitofusins 1 and 2 (Gegg et al., 2010; Geisler
et al., 2010; Sarraf et al., 2013). Some of these ubiquitinated proteins
are then bound by the autophagic protein p62/SQSMT1, which then
binds to LC3-II on the phagophore membrane (Ding et al., 2010; Lee
et al., 2010). Other OMM proteins such as FUNDC1, BNIP3, Nix, and
the mitochondrial lipid cardiolpin, have also been reported to bind
LC3-II directly following mitophagy induction (Chu et al., 2013; Ding
et al., 2010; Liu et al., 2012).
Impairment ofmitophagy is likely to contribute to themitochondrial
dysfunction observed in PD and GD. The KD or KO of PINK1 leads to mi-
tochondrial dysfunction and oxidative stress that worsens with time
(Gautier et al., 2008; Gegg et al., 2009). Restoration of mitophagy by
over expressing parkin in PINK1 KD cells reversed the inhibition of oxi-
dative phosphorylation (Gegg et al., 2010). Mitochondrial dysfunction
and oxidative stress following GCase inhibition by CBE in SH-SY5Y
cells also increased over time, with no evidence ofmitochondrial inhibi-
tion after 24 or 48 h, but increased after 10 days (Cleeter et al., 2013;
Noelker et al., 2015). In the primary cultures from GBA KO mice and
GD ﬁbroblasts, the mitochondrial dysfunction observed was coincident
with decreased macroautophagy ﬂux (de la Mata et al., 2015; Osellame
et al., 2013). Furthermore, the co-localisation of mitochondria and LC3
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(Osellame et al., 2013). These observations all imply that the degrada-
tion of mitochondria is decreased in GCase deﬁcient cells, leading to
the accumulation in cells of damaged mitochondria with impaired ETC
producing damaging reactive oxygen species.
While inhibition of mitophagy is an attractive explanation for the
mitochondrial dysfunction, it is perhaps not the full story. In theory,
blockade of mitophagy should result in the impairment of all four ETC
complexes. While there was a trend for complex IV to be decreased fol-
lowing CBE treatment of SH-SY5Y cells or in GBA KO brains, it was not
signiﬁcantly decreased like complexes I, II or III. Recently, endogenous
CoQ10 levels have been reported to be decreased in GD ﬁbroblasts, and
treatment of cells with exogenous CoQ10 partially reversed the decrease
in ATP levels and ψm (de laMata et al., 2015). CoQ10 transfers electrons
from both complexes I and II to complex III in the ETC (Hargreaves,
2014). The measurements of mitochondrial oxygen consumption and
ADP phosphorylation described above rely on endogenous CoQ10, and
therefore the reported decreases in mitochondrial function using sub-
strates for complex I and II/III, could be a result of decreased CoQ10
levels. Indeed, when Cleeter et al. measured the individual activity of
complex I by spectrophotometry in CBE-treated cells, which relies on
the addition of exogenous CoQ, therewas a trend for decreased complex
I activity but it was no longer signiﬁcant. However, the individual activ-
ity of complex I was still found to be signiﬁcantly inhibited in GBA KO
brain (Osellame et al., 2013). The reason for the decrease of CoQ10 in
the GD ﬁbroblasts is unclear and further reports are needed. Changes
in lipid/sterol metabolism as a result of GCase inhibition may impact
on the biosynthesis of CoQ10 (Hargreaves, 2014). Alternatively, CoQ10
is also known to play a role in the proton translocation across the lyso-
somalmembrane (Matalonga et al., 2014), and the lysosomal accumula-
tion of substrate in GD may have an effect on the lysosomal pool of
CoQ10. Despite the uncertainty, it is becoming increasingly clear that
treatment with CoQ10 or analogues such as MitoQ can partially reverse
the mitochondrial dysfunction and oxidative stress observed in cell
models of GD and other lysosomal storage disorders (de la Mata et al.,
2015; Matalonga et al., 2014; Osellame et al., 2013).
The accumulation of α-synuclein in a variety of GCase deﬁcient
models described above may also have an impact on mitochondrial
function. In neurons from the cortices of the D409H/D409H with
hypomorphic prosaposin mice, α-synuclein was reported to accumu-
late in mitochondria (Xu et al., 2014). Mitochondria isolated from PD
brains have been shown to have increased α-synuclein, with inhibition
of complex I of the ETC correlating with the amount of α-synuclein in
mitochondria (Devi et al., 2008). Soluble preﬁbrillar α-synuclein oligo-
mers have also beenobserved to inhibit complex I, decreaseψmanddis-
rupt calcium homeostasis (Luth et al., 2014). A similar scenario was
reported in primary cultured neurons treatedwith synthetic preformed
ﬁbrils of α-synuclein (Dryanovski et al., 2013). After two weeks these
exogenous ﬁbrils had seeded α-synuclein aggregates of endogenous
α-synuclein that resembled Lewy bodies and Lewy neurites. These
neurons presented greater mitochondrial oxidant stress compared to
their controls (Dryanovski et al., 2013).
Dysregulation of calcium can also have a profound effect on mito-
chondrial function, either by directly depolarising mitochondria
(abolishing ψm) or oxidative damage following the generation of
reactive oxygen species (Burchell et al., 2010). Calcium homeostasis is
affected in both GD and heterozygous GBAmodels, with ER-buffering
of calcium appearing to be most affected. Calcium release via the ER
ryanodine receptor has been reported to be increased from rat brain
microsomes treated with GlcCer or microsomes prepared from post-
mortem type II GD brains (Lloyd-Evans et al., 2003; Pelled et al.,
2005). Furthermore, basal cytosolic calcium levels are increased in neu-
rons differentiated from L444P/L444P and L444P/wt iPSC (Schöndorf
et al., 2014). Calcium release from the ER with the ryanodine receptor
agonist caffeine was also increased in both these types of neurons.
The expression of neuronal calcium binding protein 2 (NECAB2) wassigniﬁcantly increased in these neurons, and is likely to be a
cytoprotective response, since NECAB2 KD in the GD and heterozygous
GBAmutation neurons increased calcium-induced toxicity (Schöndorf
et al., 2014). Since GCase mutations such as N370S and L444P are
known to unfold in the ER, induce the UPR, and effect ER calcium ho-
meostasis (Mu et al., 2008; Ron and Horowitz, 2005), it is likely that
some of the changes in ER calcium handling observed in both GD and
PD lines with heterozygous GBAmutations are related to this.
Finally, neuroinﬂammation may also impact on some of the mito-
chondrial abnormalities observed in GD models. The mitochondrial
ETC is very susceptible to oxidative damage by reactive oxygen nitrogen
species such as nitric oxide (NO) and peroxinitrite, a product of NO
reactingwith the free radical superoxide produced by themitochondrial
ETC (Bolaños et al., 1994; Bolaños et al., 1995; Cleeter et al., 1994). Acti-
vated astrocytes andmicroglia produce NO, and co-culturing of neurons
with activated astrocytes results in inhibition of the neuronalmitochon-
drial ETC (Bolaños et al., 1996). Inhibition of the ETC was found to be
reversible after 24 h of co-culture, but became irreversible after 48 h
of co-culture (Stewart et al., 2000). Co-culturing of astrocytes with neu-
rons approximately doubles the levels of the antioxidant glutathione in
neurons, and this is due to the supply of glutathioneprecursors by astro-
cytes (Bolaños et al., 1996). This process limits the neuronal mitochon-
drial damage caused by astrocytic NO, as evidenced by the fact that
mitochondrial damage was worse in neurons co-cultured with activat-
ed astrocytes that did not release glutathione precursors (Gegg et al.,
2005).
Astrogliosis has been reported in type I (some with parkinsonism
and dementia) or type II GD patients (Wong et al., 2004). The evidence
of neuroinﬂammation is even greater in mouse GD models. In mice
where GBA is KO in neurons and astrocytes only, activated astrocytes
and microglia are an early event, and is closely coupled with neuronal
loss and occurs prior to manifestation of disease (Enquist et al., 2007;
Farfel-Becker et al., 2011). GlcCer accumulates in neurons throughout
the brain prior to evidence of activatedmicroglia. However, only certain
regions of the brain exhibit neurodegeneration and activated microglia,
indicating varying susceptibility of neuronal populations to GlcCer accu-
mulation (Farfel-Becker et al., 2014). Activation of glia is also seen in
mice treated with the GCase inhibitor CBE (Vitner et al., 2014), and
V394L/V394L GD mice lacking prosaposin c (Sun et al., 2010).
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